Christopher Toombs

Dr. Toombs serves as co-Founder and Chief Scientific Officer for Proniras Corporation. At Proniras, Dr. Toombs is responsible for overseeingthe tezampanel development program.

Prior to his role at Proniras, Dr. Toombs was also a co-founder and Chief Scientific Officer of Faraday Pharmaceuticals beginning in 2014. Prior to Faraday, Dr. Toombs served as Senior Director Preclinical Development at Ikaria from 2006-2011 where he was responsible for the IND enabling studies and the commencement of the first in human study of IK-1001. Before Ikaria, Dr. Toombs served in increasing roles and responsibilities in research and product development at Amgen from 1994-2006 and arrived in the Seattle area following the Amgen acquisition of Immunex in 2002.

Dr. Toombs graduated from Wheaton College with a BS in Biology and continued on to earn a PhD in Physiology-Pharmacology from the Bowman Gray School of Medicine at Wake Forest University. He completed a postdoctoral tenure at Upjohn Laboratories and is a current Diplomate of the American Board of Toxicology.